1-(4-氯苯基)磺酰基-1-甲基-3-丙基脲 | 60153-02-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-氯苯基)磺酰基-1-甲基-3-丙基脲
• 英文名称: 1-methyl-1-<(4-chlorophenyl)sulfonyl>-3-(n-propyl)urea
• 英文别名: 1-methyl-1-(4-chlorophenyl)sulfonyl-3-n-propylurea；1-Chloro-4-((methyl((propylamino)carbonyl)amino)sulfonyl)benzene；1-(4-chlorophenyl)sulfonyl-1-methyl-3-propylurea
• CAS: 60153-02-8
• 化学式: C₁₁H₁₅ClN₂O₃S
• 分子量: 290.771
• InChiKey: GHPCICSQWQDZLM-UHFFFAOYSA-N

物化性质

• 密度：
  1.307±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(4-氯苯基)磺酰基-1-甲基-3-丙基脲 在 sodium hydroxide 作用下， 生成 正丙胺 、 4-氯-N-甲基苯磺酰胺
  参考文献：
  名称：

  Evidence for an isocyanate formation in the alkaline hydrolysis of N¹-alkyl derivatives of chlorpropamide, inhibitors of aldehyde dehydrogenase

  摘要：

  异氰酸丙酯中间体的捕获和活化熵数据与醛脱氢酶抑制剂 1-烷基-1-[(4-氯苯基)磺酰基]-3-正丙基脲（氯丙酰胺的 N1-烷基衍生物）水解的消除-加成机制 AxhDH+ DN(E1cB) 相一致。

  DOI：

  10.1039/c39930000946
• 作为产物：
  描述：

  异氰酸丙酯 、 4-氯-N-甲基苯磺酰胺 在 三乙胺 作用下， 以83%的产率得到1-(4-氯苯基)磺酰基-1-甲基-3-丙基脲
  参考文献：
  名称：

  Acetylative cleavage of (arylsulfonyl)ureas to N-acetylarenesulfonamides and isocyanates

  摘要：

  DOI：

  10.1021/jo00224a077

文献信息

• Prodrugs of Nh-acidic compounds
  申请人：ALKERMES PHARMA IRELAND LIMITED

  公开号：US10723728B2

  公开（公告）日：2020-07-28

  The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.

  本发明提供了一种持续给药含有内酰胺、酰亚胺、酰胺、磺酰胺、氨基甲酸酯或脲的母体药物的方法，其方法是向患者给药有效量的本发明原药化合物，给药后，母体药物从原药中持续释放。适用于本发明方法的原药化合物是通过羰基连接的原药分子进行衍生的母药的易变共轭物。本发明的原药化合物可用于治疗任何含有内酰胺、亚胺、酰胺、磺酰胺、氨基甲酸酯或脲的母药可用于治疗的病症。
• N1-alkyl-substituted derivatives of chlorpropamide as inhibitors of aldehyde dehydrogenase
  作者：Herbert T. Nagasawa、James A. Elberling、Eugene G. DeMaster、Frances N. Shirota

  DOI：10.1021/jm00126a032

  日期：1989.6

  On the basis of an earlier observation that the N1-ethyl derivative of the hypoglycemic agent chlorpropamide (CP) inhibited aldehyde dehydrogenase (AlDH) in rats without producing hypoglycemia, we undertook a structure-activity study to assess the effect of altering the alkyl substituents at N1 and N3, as well as substituting O for N at the latter position, and evaluated these analogues for their effect on AlDH in vivo and in vitro. Our results suggest that only those CP analogues that can release alkyl isocyanates nonenzymatically inhibited AlDH. Increasing the steric bulk of the N1-alkyl substituent enhanced isocyanate formation and AlDH inhibition. CP analogues that lacked the NH group at N3 or were otherwise incapable of alkyl isocyanate release were inactive.
• NAGASAWA, H. T.;SMITH, W. E.;KWON, CHUL-HOON;GOON, D. J. W., J. ORG. CHEM., 1985, 50, N 24, 4993-4996
  作者：NAGASAWA, H. T.、SMITH, W. E.、KWON, CHUL-HOON、GOON, D. J. W.

  DOI：——

  日期：——
• PRODRUGS OF NH-ACIDIC COMPOUNDS
  申请人：Alkermes Pharma Ireland Limited

  公开号：EP2445343B1

  公开（公告）日：2021-08-04
• Multi-API Loading Prodrugs
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20160024011A1

  公开（公告）日：2016-01-28

  The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam-amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.